1. Home
  2. PTIX vs SHPH Comparison

PTIX vs SHPH Comparison

Compare PTIX & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PTIX
  • SHPH
  • Stock Information
  • Founded
  • PTIX 1994
  • SHPH 2012
  • Country
  • PTIX United States
  • SHPH United States
  • Employees
  • PTIX N/A
  • SHPH N/A
  • Industry
  • PTIX Biotechnology: Pharmaceutical Preparations
  • SHPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • PTIX Health Care
  • SHPH Health Care
  • Exchange
  • PTIX Nasdaq
  • SHPH Nasdaq
  • Market Cap
  • PTIX 2.0M
  • SHPH 2.2M
  • IPO Year
  • PTIX 2016
  • SHPH 2022
  • Fundamental
  • Price
  • PTIX $0.42
  • SHPH $0.43
  • Analyst Decision
  • PTIX
  • SHPH
  • Analyst Count
  • PTIX 0
  • SHPH 0
  • Target Price
  • PTIX N/A
  • SHPH N/A
  • AVG Volume (30 Days)
  • PTIX 324.0K
  • SHPH 262.2K
  • Earning Date
  • PTIX 05-14-2025
  • SHPH 05-12-2025
  • Dividend Yield
  • PTIX N/A
  • SHPH N/A
  • EPS Growth
  • PTIX N/A
  • SHPH N/A
  • EPS
  • PTIX N/A
  • SHPH N/A
  • Revenue
  • PTIX N/A
  • SHPH N/A
  • Revenue This Year
  • PTIX N/A
  • SHPH N/A
  • Revenue Next Year
  • PTIX N/A
  • SHPH N/A
  • P/E Ratio
  • PTIX N/A
  • SHPH N/A
  • Revenue Growth
  • PTIX N/A
  • SHPH N/A
  • 52 Week Low
  • PTIX $0.18
  • SHPH $0.33
  • 52 Week High
  • PTIX $1.87
  • SHPH $4.71
  • Technical
  • Relative Strength Index (RSI)
  • PTIX 67.76
  • SHPH 38.06
  • Support Level
  • PTIX $0.18
  • SHPH $0.35
  • Resistance Level
  • PTIX $0.28
  • SHPH $0.46
  • Average True Range (ATR)
  • PTIX 0.04
  • SHPH 0.05
  • MACD
  • PTIX 0.01
  • SHPH 0.01
  • Stochastic Oscillator
  • PTIX 62.39
  • SHPH 43.40

About PTIX Protagenic Therapeutics Inc.

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

About SHPH Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.

Share on Social Networks: